Research highlights failure to sustain reductions in TSNA levels of cigarettes

NewsGuard 100/100 Score

Tobacco-specific nitrosamines (TSNAs) are potent carcinogens formed predominantly during the cigarette manufacturing process. Despite initial success lowering TSNA levels in cigarettes sold in Canada, following subsidies by the Ontario government to manufacturers in 2000, a study published today in the journal Nicotine & Tobacco Research has found that the decrease in TSNAs have not been sustained.

The authors reviewed TSNA levels in unburned tobacco and in tobacco smoke from cigarettes produced by manufacturers that constitute 90% of Canada's cigarette market. Following initial reductions, TSNA levels in cigarettes sold in Canada consistently increased after 2007. By 2012, the levels were 2 to 40 times higher than those observed in 2007.

Though TSNA levels at the end of the study period were still below those before government subsidies, the increases raise several important issues. "Overall, the findings indicate alarming increases in the TSNA levels of cigarettes sold in Canada," says co-author Dr. David Hammond, researcher at the School of Public Health & Health Systems at the University of Waterloo. While the increases in TSNAs should not be interpreted as a direct increase in health risk, Hammond says "manufacturers bear a responsibility to minimize consumer exposure to potent carcinogens to the fullest extent possible. The failure to sustain these reductions signifies a lack of commitment towards harm reduction."​

Source: Oxford University Press USA

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis